Real-World Outcomes of Faricimab Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema

References

• Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106–16. doi:10.1016/s2214-109x(13)70145-1
   PubMed Web of Science ®Google Scholar
• Stahl A. The diagnosis and treatment of age-related macular degeneration. Dtsch Arztebl Int. 2020;117(29–30):513–520. doi:10.3238/arztebl.2020.0513
   PubMed Web of Science ®Google Scholar
• Khanna S, Komati R, Eichenbaum DA, Hariprasad I, Ciulla TA, Hariprasad SM. Current and upcoming anti-VEGF Therapies and dosing strategies for the treatment of Neovascular AMD: a comparative review. BMJ Open Ophthalmol. 2019;4(1):e000398. doi:10.1136/bmjophth-2019-000398
   PubMed Web of Science ®Google Scholar
• Chandra S, Arpa C, Menon D, et al. Ten-year outcomes of antivascular endothelial growth factor therapy in neovascular age-related macular degeneration. Eye. 2020;34(10):1888–1896. doi:10.1038/s41433-020-0764-9
   PubMed Web of Science ®Google Scholar
• Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye and Vision. 2015;2(1):17. doi:10.1186/s40662-015-0026-2
   Google Scholar
• Yau JWY, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556–564. doi:10.2337/dc11-1909
   PubMed Web of Science ®Google Scholar
• Amoaku WM, Ghanchi F, Bailey C, et al. Diabetic retinopathy and Diabetic Macular Oedema Pathways and Management: UK Consensus Working Group. Eye. 2020;34(S1):1–51. doi:10.1038/s41433-020-0961-6
   PubMedGoogle Scholar
• Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema. Ophthalmology. 2012;119(4):789–801. doi:10.1016/j.ophtha.2011.12.039
   PubMed Web of Science ®Google Scholar
• Brown DM, Schmidt-Erfurth U, Do DV, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2015;122(10):2044–2052. doi:10.1016/j.ophtha.2015.06.017
   PubMed Web of Science ®Google Scholar
• Virgili G, Parravano M, Evans JR, Gordon I, Lucenteforte E. Anti-vascular endothelial growth factor for Diabetic Macular Oedema: a Network Meta-analysis. Cochrane Database Syst Rev. 2018;2018(10):CD007419. doi:10.1002/14651858.cd007419.pub6
   Google Scholar
• Spooner KL, Guinan G, Koller S, Hong T, Chang AA. Burden Of Treatment Among Patients Undergoing Intravitreal Injections For Diabetic Macular Oedema In Australia. Diabetes Metab Syndrome Obesity. 2019;12:1913–1921. doi:10.2147/dmso.s214098
   PubMed Web of Science ®Google Scholar
• Okada M, Mitchell P, Finger RP, et al. Nonadherence or nonpersistence to intravitreal injection therapy for neovascular age-related macular degeneration. Ophthalmology. 2021;128(2):234–247. doi:10.1016/j.ophtha.2020.07.060
   PubMed Web of Science ®Google Scholar
• Adamis AP, Brittain CJ, Dandekar A, Hopkins JJ. Building on the success of anti-vascular endothelial growth factor therapy: a vision for the next decade. Eye. 2020;34(11):1966–1972. doi:10.1038/s41433-020-0895-z
   PubMed Web of Science ®Google Scholar
• Sharma A, Kumar N, Kuppermann BD, Bandello F, Loewenstein A. Faricimab: expanding horizon beyond VEGF. Eye. 2019;34(5):802–804. doi:10.1038/s41433-019-0670-1
   PubMed Web of Science ®Google Scholar
• Heier JS, Khanani AM, Quezada Ruiz C, et al. Efficacy, durability, and safety of Intravitreal Faricimab up to every 16 weeks for neovascular age-related macular degeneration (Tenaya and Lucerne): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399(10326):729–740. doi:10.1016/s0140-6736(22)00010-1
   PubMed Web of Science ®Google Scholar
• Wykoff CC, Abreu F, Adamis AP, et al. Efficacy, durability, and safety of Intravitreal Faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022;399(10326):741–755. doi:10.1016/s0140-6736(22)00018-6
   PubMed Web of Science ®Google Scholar
• Ciulla TA, Pollack JS, Williams DF. Visual acuity outcomes and anti-VEGF therapy intensity in diabetic MACULAR OEDEMA: a real-world analysis of 28 658 Patient Eyes. Br J Ophthalmol. 2020;105(2):216–221. doi:10.1136/bjophthalmol-2020-315933
   PubMed Web of Science ®Google Scholar
• Holz FG, Tadayoni R, Beatty S, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. 2014;99(2):220–226. doi:10.1136/bjophthalmol-2014-305327
   PubMed Web of Science ®Google Scholar
• Rush RB. One-year outcomes of Faricimab treatment for AFLIBERCEPT-resistant neovascular age-related macular degeneration. Clin Ophthalmol. 2023;17:2201–2208. doi:10.2147/opth.s424315
   PubMed Web of Science ®Google Scholar
• Leung EH, Oh DJ, Alderson SE, et al. Initial real-world experience with Faricimab in treatment-resistant neovascular age-related macular degeneration. Clin Ophthalmol. 2023;17:1287–1293. doi:10.2147/opth.s409822
   PubMed Web of Science ®Google Scholar
• Khanani AM, Aziz AA, Khan H, et al. The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the Truckee Study – 6 month results. Eye. 2023. doi:10.1038/s41433-023-02553-5
   Google Scholar
• Pandit SA, Momenaei B, Wakabayashi T, et al. Clinical outcomes of Faricimab in patients with previously treated neovascular age-related macular degeneration. Ophthalmol Retina. 2023. doi:10.1016/j.oret.2023.10.018
   Google Scholar
• Kataoka K, Itagaki K, Hashiya N, et al. Six-month outcomes of switching from AFLIBERCEPT to faricimab in refractory cases of neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2023;262(1):43–51. doi:10.1007/s00417-023-06222-x
   PubMed Web of Science ®Google Scholar
• Szigiato A, Mohan N, Talcott KE, et al. Short-term outcomes of Faricimab in patients with neovascular age-related macular degeneration on prior Anti-VEGF Therapy. Ophthalmol Retina. 2024;8(1):10–17. doi:10.1016/j.oret.2023.08.018
   PubMedGoogle Scholar
• Rush RB. One year results of Faricimab for aflibercept-resistant diabetic macular edema. Clin Ophthalmol. 2023;17:2397–2403. doi:10.2147/opth.s424314
   PubMed Web of Science ®Google Scholar
• Kusuhara S, Kishimoto-Kishi M, Matsumiya W, Miki A, Imai H, Nakamura M. Short-term outcomes of Intravitreal faricimab injection for diabetic macular edema. Medicina. 2023;59(4):665. doi:10.3390/medicina59040665
   PubMedGoogle Scholar
• Ohara H, Harada Y, Hiyama T, Sadahide A, Minamoto A, Kiuchi Y. Faricimab for diabetic macular edema in patients refractory to ranibizumab or aflibercept. Medicina. 2023;59(6):1125. doi:10.3390/medicina59061125
   PubMedGoogle Scholar
• Stanga PE, Valentín-Bravo FJ, Stanga SE, Reinstein UI, Pastor-Idoate S, Downes SM. Faricimab in neovascular AMD: first report of real-world outcomes in an independent Retina Clinic. Eye. 2023;37(15):3282–3289. doi:10.1038/s41433-023-02505-z
   PubMed Web of Science ®Google Scholar
• Raimondi R, Falfeli T, Bogdanova-Bennet A, et al. Outcomes of treatment-resistant neovascular age-related macular degeneration switched from aflibercept to Faricimab. Ophthalmol Retina. 2023. doi:10.1016/j.oret.2023.11.015
   PubMedGoogle Scholar
• Rudnicka AR, Jarrar Z, Wormald R, Cook DG, Fletcher A, Owen CG. Age and gender variations in age-related macular degeneration prevalence in populations of European ancestry: a meta-analysis. Ophthalmology. 2012;119(3):571–580. doi:10.1016/j.ophtha.2011.09.027
   PubMed Web of Science ®Google Scholar
• Mathur R, Bhaskaran K, Edwards E, et al. Population trends in the 10-year incidence and prevalence of diabetic retinopathy in the UK: a cohort study in the clinical practice research datalink 2004–2014. BMJ Open. 2017;7(2):e014444. doi:10.1136/bmjopen-2016-014444
   PubMed Web of Science ®Google Scholar
• Jones R, Stratton IM, Scanlon PH, Theodoropoulou S. Disengagement and loss to follow-up in Intravitreal injection clinics for neovascular age-related macular degeneration. Eye. 2023;37(15):3186–3190. doi:10.1038/s41433-023-02474-3
   PubMed Web of Science ®Google Scholar
• Rozon J-P, Hébert M, Laverdière C, et al. Delayed follow-up in patients with neovascular age-related macular degeneration treated under Universal Health Coverage. Retina. 2022;42(9):1693–1701. doi:10.1097/iae.0000000000003512
   PubMed Web of Science ®Google Scholar
• Malhotra NA, Muste J, Hom GL, Conti TF, Greenlee TE, Singh RP. Race and socioeconomic status in anti-VEGF treatment of diabetic macular edema. Ophthalmic Surg Lasers Imaging Retina. 2021;52(11):578–585. doi:10.3928/23258160-20211018-01
   PubMed Web of Science ®Google Scholar